A Phase 3 interventional study of BCX7353 capsules and BCX7353 capsules in Hereditary Angioedema, HAE, sponsored by BioCryst Pharmaceuticals. Completed at 10 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-07-19.
Sponsored by BioCryst Pharmaceuticals · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing berotralstat in Angioedemas, Hereditary — 1 open to participants now, 2 under way, 2 of them phase 3. berotralstat · Angioedemas, Hereditary.
Among the 11 studies testing berotralstat in Angioedemas, Hereditary, this one is the 11th largest by enrollment, is one of 3 that started in 2018, is one of 4 in phase 3, and was the 9th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →1 of the 11 studies testing berotralstat in Angioedemas, Hereditary is open now, in 11 countries. Recruiting first, the newest first:
BioCryst Pharmaceuticals · Sites in Canada, Czechia, France and 8 more countries
Ages 2+
By country, each count listing its studies:
berotralstat: first FDA approval 2020 (ORLADEYO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 5
First in 2015; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 58 across the 11 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
BioCryst Pharmaceuticals is the lead sponsor of 54 studies on the registry; 1 is open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals: 2 open now, 5 under way, 4 of them phase 3. Of 16 finished, 7 (44%) have results posted.
Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, this one is the 19th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2018, is one of 7 in phase 3, and was the 14th registered.
BioCryst Pharmaceuticals’s Angioedemas, Hereditary studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing berotralstat in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BioCryst Pharmaceuticals’s 22 in Angioedemas, Hereditary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE who live in Japan.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BCX7353 capsules administered orally once daily
Drug: BCX7353 capsules
BCX7353 capsules administered orally once daily
Drug: BCX7353 capsules
Matching placebo oral capsules administered orally once daily
Drug: Placebo oral capsule
BCX7353 capsules administered orally once daily
BCX7353 capsules administered orally once daily
Matching placebo capsules administered orally once daily
Part 1: The Rate of Expert-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)
The angioedema event rate and the treatment comparisons between each berotralstat dose and placebo in the rate of expert-confirmed angioedema events during the entire dosing period was analyzed using a negative binomial regression model. The number of expert-confirmed angioedema events was included as the dependent variable, the treatment was included as a fixed effect, the stratification variable (baseline monthly angioedema event rate) and study (for the combined study analysis) were included as covariates, and the logarithm of duration on treatment was included as an offset variable. The estimated rate of angioedema events for each treatment group, the treatment differences expressed as the angioedema event rate ratio (berotralstat) over placebo rate ratio), and their associated 95% confidence intervals (CIs) were provided from the negative binomial regression model.
Time frame: 24 weeks
Part 2: To Evaluate the Long-term Safety and Tolerability of Berotralstat 110 and 150 mg in Subjects With HAE
The safety data was assessed for the safety population for subjects who entered Part 2, and includes TEAEs that occurred in Part 1 and Part 2 for these subjects with a data cut-off date of 10-April-2020. TEAEs are defined as AEs that occurred on or after first dose of study treatment, whether in Part 1 or 2, and were assigned to the relevant treatment depending on when the TEAE began (Part 1 or Part 2 treatment). TEAEs were assessed for severity (graded) using the Division of Microbiology and Infectious Disease (DMID) criteria for grading AEs. TEAEs not covered by the DMID criteria were assessed as Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3) or Life-threatening (Grade 4).
Time frame: Part 1: 24 weeks (Week 0 to 24 to 52), Part 2: 28 weeks (Week 24 to 52)
Part 3: To Evaluate the Long-term Safety and Tolerability of Berotralstat Administered QD Over a 52- to up to 104-week Administration Period in Subjects With HAE.
The safety data was assessed for the safety population for subjects who entered Part 3, and includes TEAEs that occurred in Part 3 for these subjects.
Time frame: Part 3: Week 52 to up to Week 104.
Part 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks.
Assessment of number and proportion of days subjects had angioedema symptoms from expert-confirmed angioedema events during Part 1.
Time frame: 24 weeks
Part 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period
The rate of expert-confirmed angioedema events for the effective treatment period gives an analysis of the efficacy of active treatment after berotralstat had reached steady-state concentrations, given the effective half-life of 150 mg berotralstat in Study BCX7353-106 (Study 106) of 89 hours.
Time frame: Day 8 through to 24 weeks
Part 1: Change From Baseline in Angioedema Quality of Life (AE-QoL) Questionnaire at Week 24 (Total Score)
Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score).
Time frame: Baseline and 24 weeks
Part 2: To Assess the Effectiveness of Berotralstat Over a 24- to 52-week Period
Monthly Attack Rate was defined as the total number of investigator-confirmed HAE attacks experienced during the treatment period adjusted for the length of a month (defined as 28 days) and the number of days the subject was on treatment during that month. The end of Month 6 was defined as the start of Part 2 treatment. For crossover subjects receiving active treatment following placebo, months were adjusted according to the date of the first dose of active treatment. Baseline investigator-confirmed attack rate was defined as the total number of investigator-confirmed HAE attacks experienced in the period between screening and first dose of study drug adjusted for the length of a month (defined as 28 days) and the number of days during that period.
Time frame: 28 weeks (Week 24 to 52)
Part 2: To Evaluate QoL Following Berotralstat Administration Over a 24- to 52-week Period.
Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). The AE-QoL is only validated for adults; however, data were collected on all adult and adolescent study subjects.
Time frame: 28 Weeks (Week 24 to 52)
Part 3: To Assess the Effectiveness of Berotralstat Over a 52- to up to 104-week Administration Period
Adjusted subject-reported event rate was defined as (total number of adjusted subject-reported HAE events experienced in the period between the Week 52 visit and end of study \[or the last dose date/time in Part 3 + 24 hours for subjects who discontinued drug in Part 3\]) \* 28/(date of last dose in Part 3 - date of Week 52 visit + 1).
Time frame: 52 weeks (Week 52 to 104)
Part 3: To Evaluate QoL Following Berotralstat Administration Over a 52- to up to 104-week Period
Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.
Time frame: 52 Weeks (Week 52 to 104)
Part 3: To Evaluate Subject's Satisfaction With Berotralstat During 52- to 104-week Administration Period
The Treatment Satisfaction Questionnaire for Medication (TSQM) was completed by subjects at baseline and at each study visit until the end of the study. TSQM scores consisted of 14 items of which 13 items were made up of 3 specific scales (Effectiveness, Side Effects, and Convenience) and 1 global satisfaction scale (Global Satisfaction). At baseline, TSQM questionnaires were completed based on subject's satisfaction with usual medications. At all other time points for collection of TSQM, subjects were asked about their level of satisfaction or dissatisfaction with the study drug. Scales scores were calculated for each scale and were transformed into scores ranging from 0 to 100, with higher scores indicating higher satisfaction. TSQM score and corresponding change from baseline values were calculated at each visit. For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.
Time frame: 52 Weeks (Week 52 to 104)
| Milestone | Berotralstat 110mg Once Daily | Berotralstat 110mg QD, Followed by Berotralstat 150 mg QD | Berotralstat 110mg QD After Placebo | Berotralstat 110mg QD, Followed by Berotralstat 150 mg QD, After Placebo | Berotralstat 150mg Once Daily | Berotralstat 150mg QD After Placebo |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 2 | 1 | 7 | 3 |
| Completed | 3 | 3 | 2 | 1 | 7 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Study drug discontinuation due to rash | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Berotralstat 110mg Once Daily | Berotralstat 110mg QD, Followed by Berotralstat 150 mg QD | Berotralstat 110mg QD After Placebo | Berotralstat 110mg QD, Followed by Berotralstat 150 mg QD, After Placebo | Berotralstat 150mg Once Daily | Berotralstat 150mg QD After Placebo |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 1 | 1 | 7 | 2 |
| Completed | 3 | 3 | 0 | 1 | 6 | 2 |
| Not completed | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lab abnormality or ae | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Berotralstat 110mg Once Daily | Berotralstat 110mg QD, Followed by Berotralstat 150 mg QD | Berotralstat 110mg QD After Placebo | Berotralstat 110mg QD, Followed by Berotralstat 150 mg QD, After Placebo | Berotralstat 150mg Once Daily | Berotralstat 150mg QD After Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 3 | 0 | 1 | 6 | 1 |
| Completed | 0 | 3 | 0 | 1 | 5 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
The angioedema event rate and the treatment comparisons between each berotralstat dose and placebo in the rate of expert-confirmed angioedema events during the entire dosing period was analyzed using a negative binomial regression model. The number of expert-confirmed angioedema events was included as the dependent variable, the treatment was included as a fixed effect, the stratification variable (baseline monthly angioedema event rate) and study (for the combined study analysis) were included as covariates, and the logarithm of duration on treatment was included as an offset variable. The estimated rate of angioedema events for each treatment group, the treatment differences expressed as the angioedema event rate ratio (berotralstat) over placebo rate ratio), and their associated 95% confidence intervals (CIs) were provided from the negative binomial regression model.
| Angioedema event rate per 28 days | Berotralstat 110mg Once Daily | Berotralstat 150mg Once Daily | Placebo |
|---|---|---|---|
| Part 1: The Rate of Expert-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168) | 1.961 ± 1.3021 | 1.089 ± 0.9168 | 2.734 ± 1.6359 |
The safety data was assessed for the safety population for subjects who entered Part 2, and includes TEAEs that occurred in Part 1 and Part 2 for these subjects with a data cut-off date of 10-April-2020. TEAEs are defined as AEs that occurred on or after first dose of study treatment, whether in Part 1 or 2, and were assigned to the relevant treatment depending on when the TEAE began (Part 1 or Part 2 treatment). TEAEs were assessed for severity (graded) using the Division of Microbiology and Infectious Disease (DMID) criteria for grading AEs. TEAEs not covered by the DMID criteria were assessed as Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3) or Life-threatening (Grade 4).
| Participants | Berotralstat 110mg Once Daily | Berotralstat 110mg QD After Placebo | Berotralstat 150mg Once Daily | Berotralstat 150mg QD After Placebo | Placebo |
|---|---|---|---|---|---|
| TEAE | 6 | 1 | 7 | 2 | 6 |
| Drug-related TEAE | 2 | 0 | 3 | 0 | 2 |
| SAE | 2 | 0 | 0 | 0 | 0 |
| Drug-related SAE | 0 | 0 | 0 | 0 | 0 |
| Grade 3 or 4 TEAE | 0 | 0 | 1 | 0 | 1 |
| Drug-related grade 3 or 4 TEAE | 0 | 0 | 1 | 0 | 0 |
| TEAE leading to interruption of study drug | 1 | 0 | 2 | 0 | 0 |
| TEAE leading to discontinuation of study drug | 0 | 0 | 1 | 0 | 1 |
| Investigator-identified rash (event of special interest) | 1 | 0 | 2 | 0 | 1 |
| GI abdominal related TEAE | 3 | 1 | 3 | 1 | 1 |
| GI abdominal related TEAE leading to discontinuation of study drug | 0 | 0 | 0 | 0 | 0 |
The safety data was assessed for the safety population for subjects who entered Part 3, and includes TEAEs that occurred in Part 3 for these subjects.
| Participants | Berotralstat 150mg Once Daily |
|---|---|
| TEAE | 6 |
| Drug-related TEAE | 0 |
| SAE | 1 |
| Drug-related SAE | 0 |
| Grade 3 or 4 TEAE | 1 |
| Drug-related grade 3 or 4 TEAE | 0 |
| TEAE leading to interruption of study drug | 0 |
| TEAE leading to discontinuation of study drug | 0 |
| Investigator-identified rash (event of special interest) | 0 |
| GI abdominal related TEAE | 0 |
| GI abdominal related TEAE leading to discontinuation of study drug | 0 |
Assessment of number and proportion of days subjects had angioedema symptoms from expert-confirmed angioedema events during Part 1.
| Proportion days with angioedema symptoms | Berotralstat 110mg Once Daily | Berotralstat 150mg Once Daily | Placebo |
|---|---|---|---|
| Part 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks. | 0.258 ± 0.0534 | 0.118 ± 0.0500 | 0.240 ± 0.0536 |
The rate of expert-confirmed angioedema events for the effective treatment period gives an analysis of the efficacy of active treatment after berotralstat had reached steady-state concentrations, given the effective half-life of 150 mg berotralstat in Study BCX7353-106 (Study 106) of 89 hours.
| Angioedema event rate per 28 days | Berotralstat 110mg Once Daily | Berotralstat 150mg Once Daily | Placebo |
|---|---|---|---|
| Part 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period | 1.988 ± 1.3422 | 1.136 ± 0.9564 | 2.775 ± 1.6472 |
Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score).
| AE-QoL Total Score Change from baseline | Berotralstat 110mg Once Daily | Berotralstat 150mg Once Daily | Placebo |
|---|---|---|---|
| Part 1: Change From Baseline in Angioedema Quality of Life (AE-QoL) Questionnaire at Week 24 (Total Score) | -9.47 ± 6.933 | -15.82 ± 6.424 | 3.18 ± 6.832 |
Monthly Attack Rate was defined as the total number of investigator-confirmed HAE attacks experienced during the treatment period adjusted for the length of a month (defined as 28 days) and the number of days the subject was on treatment during that month. The end of Month 6 was defined as the start of Part 2 treatment. For crossover subjects receiving active treatment following placebo, months were adjusted according to the date of the first dose of active treatment. Baseline investigator-confirmed attack rate was defined as the total number of investigator-confirmed HAE attacks experienced in the period between screening and first dose of study drug adjusted for the length of a month (defined as 28 days) and the number of days during that period.
| HAE attacks/28 days-change from baseline | Berotralstat 110mg Once Daily | Berotralstat 110mg QD After Placebo | Berotralstat 150mg Once Daily | Berotralstat 150mg QD After Placebo |
|---|---|---|---|---|
| Month 6 | -0.487 ± 1.0661 | -0.686 ± 0.2872 | -0.863 ± 1.3000 | -1.386 ± 0.5951 |
| Month 7 | -1.085 ± 0.8249 | -0.889 ± 0 | -1.395 ± 0.9127 | -1.403 ± 0.7948 |
| Month 8 | -0.585 ± 0.5622 | — | -1.395 ± 0.8016 | — |
| Month 9 | -0.418 ± 0.8910 | — | -0.927 ± 0.7645 | — |
| Month 10 | -0.918 ± 1.0134 | — | -0.733 ± 0.8068 | — |
| Month 11 | -0.585 ± 0.5622 | — | -1.400 ± 0.9997 | — |
| Month 12 | -0.585 ± 1.0737 | — | -0.900 ± 0.3925 | — |
| Month 13 | -0.757 ± 0.9729 | — | -0.733 ± 1.3060 | — |
Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). The AE-QoL is only validated for adults; however, data were collected on all adult and adolescent study subjects.
| AE-QoL score -change from baseline | Berotralstat 110mg Once Daily | Berotralstat 110mg QD After Placebo | Berotralstat 150mg Once Daily | Berotralstat 150mg QD After Placebo |
|---|---|---|---|---|
| Week 24 | -4.9 ± 13.0 | -19.1 ± 0 | -19.5 ± 31.2 | 0 ± 0 |
| Week 52 | -7.4 ± 9.4 | — | -17.2 ± 30.6 | — |
Adjusted subject-reported event rate was defined as (total number of adjusted subject-reported HAE events experienced in the period between the Week 52 visit and end of study \[or the last dose date/time in Part 3 + 24 hours for subjects who discontinued drug in Part 3\]) \* 28/(date of last dose in Part 3 - date of Week 52 visit + 1).
| HAE attacks per 28 days | Berotralstat 150mg Once Daily |
|---|---|
| Part 3: To Assess the Effectiveness of Berotralstat Over a 52- to up to 104-week Administration Period | 0.883 ± 1.1216 |
Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL. The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score). For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.
| AE-QoL score -change from baseline | Berotralstat 150mg Once Daily |
|---|---|
| Week 52 | -11.11 ± 29.089 |
| Week 60 | -13.24 ± 23.758 |
| Week 72 | -17.38 ± 24.998 |
| Week 84 | -11.63 ± 22.900 |
| Week 96 | -20.40 ± 32.069 |
| Week 104 | -18.93 ± 30.681 |
The Treatment Satisfaction Questionnaire for Medication (TSQM) was completed by subjects at baseline and at each study visit until the end of the study. TSQM scores consisted of 14 items of which 13 items were made up of 3 specific scales (Effectiveness, Side Effects, and Convenience) and 1 global satisfaction scale (Global Satisfaction). At baseline, TSQM questionnaires were completed based on subject's satisfaction with usual medications. At all other time points for collection of TSQM, subjects were asked about their level of satisfaction or dissatisfaction with the study drug. Scales scores were calculated for each scale and were transformed into scores ranging from 0 to 100, with higher scores indicating higher satisfaction. TSQM score and corresponding change from baseline values were calculated at each visit. For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.
| TSQM Global score -change from baseline | Berotralstat 150mg Once Daily |
|---|---|
| Week 60 | 11.7 ± 37.15 |
| Week 72 | 13.6 ± 37.72 |
| Week 84 | 11.7 ± 34.44 |
| Week 96 | 18.8 ± 26.43 |
| Week 104 | 16.1 ± 23.77 |
Collected over Adverse Events (AEs) were assessed and recorded from the time that the Informed consent form was signed until the last follow-up visit, approximately 3 weeks following the last dose of study drug, or until the AE was resolved or the subject was in a clinically stable condition with regard to the AE. AEs were assigned to the relevant treatment depending on when the AE began; i.e., Part 1 or Part 2 and 3 treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Berotralstat 110mg Once Daily | 0/8 (0%) | 2/8 (25%) | 8/8 (100%) |
| Berotralstat 150mg Once Daily | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Berotralstat 110mg Once Daily | Berotralstat 150mg Once Daily | Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/8 | 0/9 | 0/6 |
| Hereditary angioedemaCongenital, familial and genetic disorders | 1/8 | 0/9 | 0/6 |
| Ankle fractureInjury, poisoning and procedural complications | 0/8 | 1/9 | 0/6 |
| Fibula fractureInjury, poisoning and procedural complications | 0/8 | 1/9 | 0/6 |
| Event | Berotralstat 110mg Once Daily | Berotralstat 150mg Once Daily | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/8 | 4/9 | 4/6 |
| Abdominal painGastrointestinal disorders | 2/8 | 2/9 | 0/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/8 | 0/9 | 0/6 |
| InfluenzaInfections and infestations | 2/8 | 0/9 | 0/6 |
| PruritusSkin and subcutaneous tissue disorders | 0/8 | 2/9 | 0/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/8 | 2/9 | 0/6 |
| Abdominal discomfortGastrointestinal disorders | 1/8 | 0/9 | 1/6 |
| ToothacheGastrointestinal disorders | 0/8 | 0/9 | 1/6 |
| UrticariaSkin and subcutaneous tissue disorders | 0/8 | 1/9 | 1/6 |
| Arthropod biteInjury, poisoning and procedural complications | 0/8 | 0/9 | 1/6 |
| Age, Continuous(years) | Part 1: Berotralstat 110mg Once Daily | Part 1: Berotralstat 150mg Once Daily | Part 1: Placebo | Total |
|---|---|---|---|---|
| Mean | 47.3 ± 15.03 | 37.3 ± 9.05 | 42.3 ± 13.52 | 42.1 ± 12.61 |
| Sex: Female, Male(Participants) | Part 1: Berotralstat 110mg Once Daily | Part 1: Berotralstat 150mg Once Daily | Part 1: Placebo | Total |
|---|---|---|---|---|
| Female | 5 | 6 | 5 | 16 |
| Male | 1 | 1 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Part 1: Berotralstat 110mg Once Daily | Part 1: Berotralstat 150mg Once Daily | Part 1: Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 6 | 6 | 6 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Baseline expert-confirmed angioedema event rate(participants) | Part 1: Berotralstat 110mg Once Daily | Part 1: Berotralstat 150mg Once Daily | Part 1: Placebo | Total |
|---|---|---|---|---|
| ≥ 2 events/month | 2 | 4 | 3 | 9 |
| < 2 events/month | 4 | 3 | 3 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Jul 2021, 30 months.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 30 months is above that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berotralstat